909 related articles for article (PubMed ID: 25129481)
21. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of PD-L1 and PD-L2 in dermal fibroblasts from alopecia areata mice.
Li Y; Kilani RT; Pakyari M; Leung G; Nabai L; Ghahary A
J Cell Physiol; 2018 Mar; 233(3):2590-2601. PubMed ID: 28777458
[TBL] [Abstract][Full Text] [Related]
23. Plasmacytoid dendritic cells as a possible key player to initiate alopecia areata in the C3H/HeJ mouse.
Ito T; Suzuki T; Sakabe JI; Funakoshi A; Fujiyama T; Tokura Y
Allergol Int; 2020 Jan; 69(1):121-131. PubMed ID: 31431342
[TBL] [Abstract][Full Text] [Related]
24. Altered T cell subpopulations and serum anti-TYRP2 and tyrosinase antibodies in the acute and chronic phase of alopecia areata in the C3H/HeJ mouse model.
Hashimoto K; Yamada Y; Fujikawa M; Sekiguchi K; Uratsuji H; Mori S; Watanabe H; Matsumoto T
J Dermatol Sci; 2021 Oct; 104(1):21-29. PubMed ID: 34511266
[TBL] [Abstract][Full Text] [Related]
25. Which is the Ideal JAK Inhibitor for Alopecia Areata - Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway.
Sardana K; Bathula S; Khurana A
Indian Dermatol Online J; 2023; 14(4):465-474. PubMed ID: 37521227
[TBL] [Abstract][Full Text] [Related]
26. Pro-inflammatory Vδ1
Uchida Y; Gherardini J; Schulte-Mecklenbeck A; Alam M; Chéret J; Rossi A; Kanekura T; Gross CC; Arakawa A; Gilhar A; Bertolini M; Paus R
J Dermatol Sci; 2020 Nov; 100(2):129-138. PubMed ID: 33039243
[TBL] [Abstract][Full Text] [Related]
27. Effects of mesenchymal stem cell therapy on alopecia areata in cellular and hair follicle organ culture models.
Kim JE; Oh JH; Woo YJ; Jung JH; Jeong KH; Kang H
Exp Dermatol; 2020 Mar; 29(3):265-272. PubMed ID: 30372797
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of T-cell activity in alopecia areata: recent developments and new directions.
Passeron T; King B; Seneschal J; Steinhoff M; Jabbari A; Ohyama M; Tobin DJ; Randhawa S; Winkler A; Telliez JB; Martin D; Lejeune A
Front Immunol; 2023; 14():1243556. PubMed ID: 38022501
[TBL] [Abstract][Full Text] [Related]
29. iNKT cells ameliorate human autoimmunity: Lessons from alopecia areata.
Ghraieb A; Keren A; Ginzburg A; Ullmann Y; Schrum AG; Paus R; Gilhar A
J Autoimmun; 2018 Jul; 91():61-72. PubMed ID: 29680372
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-15 is a hair follicle immune privilege guardian.
Suzuki T; Chéret J; Scala FD; Rajabi-Estarabadi A; Akhundlu A; Demetrius DL; Gherardini J; Keren A; Harries M; Rodriguez-Feliz J; Epstein G; Lee W; Purba T; Gilhar A; Paus R
J Autoimmun; 2024 May; 145():103217. PubMed ID: 38581915
[TBL] [Abstract][Full Text] [Related]
31. Role of janus kinase inhibitors in the treatment of alopecia areata.
Triyangkulsri K; Suchonwanit P
Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
[TBL] [Abstract][Full Text] [Related]
32. JAK Inhibitors for Treatment of Alopecia Areata.
Wang EHC; Sallee BN; Tejeda CI; Christiano AM
J Invest Dermatol; 2018 Sep; 138(9):1911-1916. PubMed ID: 30057345
[TBL] [Abstract][Full Text] [Related]
33. Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata.
Bertolini M; Zilio F; Rossi A; Kleditzsch P; Emelianov VE; Gilhar A; Keren A; Meyer KC; Wang E; Funk W; McElwee K; Paus R
PLoS One; 2014; 9(5):e94260. PubMed ID: 24832234
[TBL] [Abstract][Full Text] [Related]
34. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity.
Petukhova L; Duvic M; Hordinsky M; Norris D; Price V; Shimomura Y; Kim H; Singh P; Lee A; Chen WV; Meyer KC; Paus R; Jahoda CA; Amos CI; Gregersen PK; Christiano AM
Nature; 2010 Jul; 466(7302):113-7. PubMed ID: 20596022
[TBL] [Abstract][Full Text] [Related]
35. Baricitinib for the Treatment of Alopecia Areata.
Freitas E; Guttman-Yassky E; Torres T
Drugs; 2023 Jun; 83(9):761-770. PubMed ID: 37195491
[TBL] [Abstract][Full Text] [Related]
36. Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences.
Yamaguchi HL; Yamaguchi Y; Peeva E
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673994
[TBL] [Abstract][Full Text] [Related]
37. Induction of alopecia areata in C3H/HeJ mice using polyinosinic-polycytidylic acid (poly[I:C]) and interferon-gamma.
Shin JM; Choi DK; Sohn KC; Koh JW; Lee YH; Seo YJ; Kim CD; Lee JH; Lee Y
Sci Rep; 2018 Aug; 8(1):12518. PubMed ID: 30131581
[TBL] [Abstract][Full Text] [Related]
38. A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata.
Deeb M; Beach RA
J Cutan Med Surg; 2017; 21(6):562-563. PubMed ID: 28635319
[TBL] [Abstract][Full Text] [Related]
39. The antiinflammatory effects of Xuefu Zhuyu decoction on C3H/HeJ mice with alopecia areata.
He X; Duan X; Liu J; Sha X; Gong Y; Lu W; Li Z; Chen X; Li Y; Shen Z
Phytomedicine; 2021 Jan; 81():153423. PubMed ID: 33310308
[TBL] [Abstract][Full Text] [Related]
40. Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(-) cells promote systemic alopecia areata and CD4(+)/CD25(+) cells blockade disease onset in the C3H/HeJ mouse model.
McElwee KJ; Freyschmidt-Paul P; Hoffmann R; Kissling S; Hummel S; Vitacolonna M; Zöller M
J Invest Dermatol; 2005 May; 124(5):947-57. PubMed ID: 15854035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
